Intravesical bacillus Calmette-Guérin is the current first-line treatment for high-grade nonmuscle-invasive bladder cancer; however, a substantial proportion of patients are unresponsive to bacillus Calmette-Guérin treatment. While cystectomy...
Japan BCG Laboratory, Tokyo, Japan) instillations, which is one of the standard regimens as outlined by the Clinical Practice Guidelines for Bladder Cancer 2019 by the Japanese Urological Association. However, he developed a fever (38 °C...
Purpose To evaluate the clinical and pharmacoeconomic impact on the treatment of patients with bladder cancer as result of an international lack of BCG, which lasted for several months. Materials and methods A retrospective analysis was conducted on BCG patients treated during the drug shortage (Jan...
At present, BCG intravesical instillation therapy is considered a very effective treatment modality for superficial bladder cancer. In this paper, the present status of BCG intravesical treatment was discussed along with speculation on the future directions of BCG treatment for this malignant disease....
abut do not like their pension 但是不喜欢他们的养老金[translate] aBCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. BCG斡旋的膀胱癌免疫疗法: 辨认治疗反应定列式使用一个被校准的数学模型。[translate]...
OncoTherad (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway OncoTherad (MRB-CFI-1) could be considered a promising therapy in the treatment of NMIBC.doi:10.1016/j.tice.2022.101762I B.Reis... IB ...
In this article, we discuss the treatment guidelines for non-muscle invasive bladder cancer and therapeutic approaches under investigation in clinical trials. Expert opinion: The FDA is currently allowing single-arm studies as a pathway for approval in BCG-refractory patients with CIS. Although many ...
EP: 1.Overview of Non-Muscle Invasive Bladder Cancer (NMIBC) EP: 2.Appropriate Risk Stratification Intermediate and high-risk Risk Classification EP: 3.Adapting Urology Practices in the Face of BCG Shortages EP: 4.Initial Treatment Selection for NMIBC in the Era of BCG Shortage ...
Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.This is a modal window. This video is either unavailable or not supported in this browserError Code: MEDIA_ERR_SRC_NOT_SUPPORTEDTechnical details : The...
Herein, we examined the use of BCG vaccine treatment in patients with NMIBC and the risk of death and dementia. To our knowledge, we present the largest-to-date population health study of intravesical BCG vaccine for bladder cancer and ADRD, using electronic health records from patients ...